Back to Search
Start Over
Inflammatory bowel disease: a positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism
- Source :
- Scandinavian journal of gastroenterology
- Publication Year :
- 2002
-
Abstract
- Background: Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease respond to infliximab treatment. The ability or inability to respond seems to persist over time. Biological characteristics and/or genetic background can influence the response to treatment. The aim was to assess the value of C-reactive protein and TNF- α serum levels before treatment as well as the TNF -308 gene polymorphism in the prediction of response to infliximab treatment in Crohn disease. Methods: Two-hundred-and-twenty-six Crohn disease patients treated in the setting of an expanded access programme to infliximab in Belgium were studied. There were 136 refractory luminal diseases and 90 refractory fistulizing diseases. Luminal diseases were treated with one single infusion; fistulizing diseases with three infusions at weeks 0, 2 and 6. A clinical response to treatment was defined as either a Crohn disease activity index
Details
- Language :
- English
- ISSN :
- 00365521
- Database :
- OpenAIRE
- Journal :
- Scandinavian journal of gastroenterology
- Accession number :
- edsair.doi.dedup.....0d611ede11cc73d6910cd40f246291fe